TG Therapeutics has crossed from launch-story biotech into a single-product commercial franchise, and the June quarter made that shift hard to ignore. BRIUMVI, the company's glycoengineered anti-CD20 infusion for relapsing multiple sclerosis, delivered $228 million of United States net product revenue and again outran the company's own sales target. That print prompted a second guidance raise of the year. Management now aims to exit the year at a billion-dollar annualized United States run rate. That commercial proof is the bull case in miniature. The bear case sits in the same print: reported earnings compressed even as the top line accelerated, because the company chose to spend ahead of a subcutaneous formulation and a second manufacturing source.
The income statement is where the argument splits. Total revenue climbed to $240 million. Net income fell to $8 million. The gap is not a demand problem. Research and development absorbed a $55 million manufacturing charge tied to the subcutaneous program and a secondary source. Strip that charge and operating income would have been about $76 million. Shareholders are being asked to treat the earnings miss as a reinvestment cycle rather than a franchise stall. Roche's Ocrevus and Novartis's Kesimpta still dominate the anti-CD20 category, so the spend only pays if persistence and treatment-naive starts keep compounding after the infusion schedule is simplified.
Sequential United States growth of seventeen percent, a second consecutive record in new patient starts, and persistence that management says exceeded internal plans are the operating facts underneath the raise. Full-year United States BRIUMVI guidance now sits at $890 million at the low end. Global revenue is targeted near $950 million. The equity already prices a clean path to a billion-dollar run rate plus a successful subcutaneous expansion. Does the next year of starts, the ENHANCE label work, and the Phase III subcutaneous readout confirm that duration, or does a single-product, levered franchise stop being worth a growth-biotech multiple once the easy switchers are gone?